Streetbeat News

Regulatory

CMPX

Compass Therapeutics (NASDAQ:CMPX) has completed patient enrollment for its COMPANION-002 Phase 2/3 trial of CTX-009 in combination with paclitaxel for biliary tract cancer. The company also approved an Investigator Sponsored Trial (IST) of CTX-009 in the first-line setting for BTC patients.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:14 pm

SPY

Jim Cramer suggests that a Trump presidency could be beneficial for income earners and investors, citing potential tax cuts. However, there are concerns about increased tariffs, inflation, and higher mortgage rates. The SPDR S&P 500 ETF Trust (SPY) rose 0.90% despite recent sell-offs.

Portfolio Pulse from Shanthi Rexaline

August 06, 2024 | 12:13 pm

FXI

TSLA

Tesla is recalling 1,683,627 cars in China, as reported by Bloomberg citing CCTV.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:12 pm

CLNN

Clene Inc. (NASDAQ: CLNN) has submitted new biomarker and clinical efficacy data to the FDA for its CNM-Au8 treatment for ALS. The data shows significant clinical improvements in survival and functional status for treated participants, supporting a dual mechanism of action. This submission aims to guide an FDA Type C interaction for an accelerated approval pathway.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:07 pm

RVPH

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced the grant of U.S. Patent 12053477 for the use of brilaroxazine in treating idiopathic pulmonary fibrosis (IPF) and other conditions. The drug has also received Orphan Drug Designation from the FDA.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:04 pm

TNXP

Tonix Pharmaceuticals announced the publication of a research paper in Microorganisms, highlighting their high-throughput, high-content imaging technology for screening convalescent sera to generate neutralizing antibodies against SARS-CoV-2 variants. The study underscores Tonix's R&D capabilities, including a COVID-19 vaccine selected by NIH for Project NextGen and a host-directed anti-viral program awarded a DoD/DTRA contract for up to $34 million.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:03 pm

MULN

Mullen Automotive has announced that it has met all federal and state regulatory requirements for its Class 1 and Class 3 commercial vehicles. The company is actively manufacturing and selling these vehicles across the US. Mullen's total assets are expected to be approximately $191.4 million as of June 30.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:03 pm

HRMY

Harmony Biosciences announced that it is on track to submit a supplemental new drug application (sNDA) for Pitolisant in the treatment of idiopathic hypersomnia by Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:58 am

JOBY

Joby Aviation shares are trading higher after the company announced it has formally applied for its revolutionary aircraft to be certified for use in Australia.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:49 am

OKYO

OKYO Pharma has been granted a European patent for its novel OK-101 chemerin analogs, enhancing its intellectual property portfolio.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:09 am